Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC Linker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (9) ADC Cytotoxin (12) ADC Linker (896) Drug-Linker Conjugates for ADC (289) E3 Ligase Ligand-Linker Conjugates (3) PROTAC-Linker Conjugates for PAC (2) Target Protein Ligand-Linker Conjugates (1) Amino Acid Derivatives (2) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (70) Antifolate (1) Apoptosis (20) Autophagy (1) Bacterial (7) Biochemical Assay Reagents (3) c-Met/HGFR (3) CCR (6) CD22 (3) CDK (1) DNA Alkylator/Crosslinker (5) DNA/RNA Synthesis (2) Drug Intermediate (1) EGFR (12) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (3) FGFR (1) Glucocorticoid Receptor (3) Guanylate Cyclase (1) Interleukin Related (1) Isotope-Labeled Compounds (9) Kinesin (1) Mesothelin (1) Microtubule/Tubulin (54) Mucin (1) NAMPT (2) Nectin-4 (2) Notch (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) PROTAC Linkers (209) PROTACs (4) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (2) Sodium Channel (4) Sodium Phosphate Cotransporter (1) STING (3) TAM Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (45) TROP2 (2)
By Research Areas:	Cancer (1250) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (41) Neurological Disease (1)
Click Chemistry:	ADC Synthesis (277) TCO (23) Labeling and Fluorescence Imaging (1) DBCO (69) PROTAC Synthesis (55) Azide (87) BCN (33) Tetrazine (49) Alkynes (58)

1295

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

312

Click Chemistry

Targets Recommended: ADC Linker Drug-Linker Conjugates for ADC ADC Cytotoxin ADC Antibody Target Protein Ligand-Linker Conjugates PROTAC-Linker Conjugates for PAC E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160157

IM-2	Drug-Linker Conjugates for ADC	Cancer
IM-2 is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-156813

Fmoc-Val-Ala-aminomethyl acetate	ADC Linker	Cancer
Fmoc-Val-Ala-aminomethyl acetate (Compound 58b) is an **ADC Linker*, and can be used for synthesis of ADCs* .

HY-131833

Fmoc-Gly-Gly-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-41541

Tetraethylene glycol monotosylate Tos-PEG4	ADC Linker PROTAC Linkers	Cancer
Tetraethylene glycol monotosylate is a cleavable and acylhydrazone-based **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) . Tetraethylene glycol monotosylate also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-47968

SC209 intermediate-1	ADC Linker	Cancer
SC209 intermediate-1 (Compound A7a) is an ADC linker. SC209 intermediate-1 can be used for synthesis of ADCs .

HY-118759

DSP Crosslinker 1 Publications Verification	ADC Linker	Inflammation/Immunology
DSP Crosslinker is a cleavable **ADC linker*, used in the synthesis of antibody-drug conjugates (ADCs*) .

HY-176455

**ADC-5 drug-linker**	Drug-Linker Conjugates for ADC	Cancer
ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452) .

HY-126670

mDPR(Boc)-Val-Cit-PAB	ADC Linker	Cancer
mDPR(Boc)-Val-Cit-PAB is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC) .

HY-W352966

Mal-PEG2-CH2COOH	ADC Linker	Cancer
Mal-PEG2-CH2COOH is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-160776

Diazido-methyltetrazine tri-arm	ADC Linker	Cancer
Diazido-methyltetrazine tri-arm is a polyvalent ADC linker and can be used for synthesis of ADCs .

HY-114697

DSG Crosslinker 1 Publications Verification Disuccinimidyl glutarate	ADC Linker	Inflammation/Immunology
DSG Crosslinker is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-160790

β-Glu-PNP	ADC Linker	Cancer
β-Glu-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-169353

Mal-Exo-EEVC	ADC Linker	Cancer
Mal-Exo-EEVC is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugate (ADC) .

HY-117409

Aminoethyl-SS-ethylalcohol	ADC Linker	Cancer
Aminoethyl-SS-ethylalcohol is a glutathione cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135418

Fmoc-Asp-NH2	ADC Linker	Cancer
Fmoc-Asp-NH2 is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

HY-173633

BrAc-Val-Ala	ADC Linker	Cancer
BrAc-Val-Ala is an **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs), such as ABBV-969 .

HY-117050

PEG12-Tos	ADC Linker PROTAC Linkers	Cancer
Tos-PEG12 is a noncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). PEG12-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-P5299

Fmoc-Gly-Gly-OSu	Biochemical Assay Reagents	Others
Fmoc-Gly-Gly-OSu (Compound 98-6) is a dipeptide that can be used to synthesize ADC linker .

HY-400191A

Fmoc-Gly-Gly-allyl propionate	ADC Linker	Cancer
Fmoc-Gly-Gly-allyl propionate is a cleavable linker that can be used to synthesize Antibody-Drug Conjugates (ADCs) .

HY-42745

m-PEG2-Tos	ADC Linker PROTAC Linkers	Cancer
m-PEG2-Tos is a uncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG2-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-164146

BCN-HS-PEG2(vcPABC-MMAE)2	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
BCN-HS-PEG2(vcPABC-MMAE)2 is a drug-linker conjugate for ADC consists an ADC linker and a tubulin polymerization inhibitor MMAE (HY-15162). BCN-HS-PEG2(vcPABC-MMAE)2 can be used in the synthesis of antibody-agent conjugates (ADCs) .

HY-148461

Mal-VC-PAB-PNP	ADC Linker	Cancer
Mal-VC-PAB-PNP is a cleavable **ADC linker*. Mal-VC-PAB-PNP can be used in the synthesis of antibody-drug conjugates (ADCs*) .

HY-148463

MP-Ala-Ala-PAB	ADC Linker	Cancer
MP-Ala-Ala-PAB is a cleavable **ADC linker*. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs*) .

HY-148462

Fmoc-Ala-Ala-PAB	ADC Linker	Cancer
Fmoc-Ala-Ala-PAB is a cleavable **ADC linker*. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs*) .

HY-148464

MC-Ala-Ala-PAB	ADC Linker	Cancer
MC-Ala-Ala-PAB is a cleavable **ADC linker*. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs*) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833A

Fmoc-Gly-Gly-D-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-D-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OH is the D-isomer of Fmoc-Gly-Gly-Phe-OH (HY-131833).

HY-139353

Fmoc-Phe-Lys(Boc)-PAB	ADC Linker	Cancer
Fmoc-Phe-Lys(Boc)-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-169352

Mal-Exo-EVC	ADC Linker	Cancer
Mal-Exo-EVC is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugate (ADC) .

HY-160181

INX-SM-3	Glucocorticoid Receptor	Inflammation/Immunology
INX-SM-3 is a novel glucocorticosteroid . INX-SM-3 can be used as a glucocorticosteroid-linker connected to ADCs .

HY-43279

Fmoc-Gly-NH-CH2-O-CH2COOH	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-O-CH2COOH is an ADC linker. Fmoc-Gly-NH-CH2-O-CH2COOH can be used for synthesis of ADCs .

HY-125933

Val-Ala-PAB	ADC Linker	Cancer
Val-Ala-PAB is a cleavable ADC linker that can be used for ADCs synthesis .

HY-131990

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH	ADC Linker	Cancer
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-130818

N-(5-Hydroxypentyl)maleimide	ADC Linker	Cancer
N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ) .

HY-131990A

MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH	ADC Linker	Cancer
MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-148871

Mc-Val-Cit-PAB-Gefitinib chloride	Drug-Linker Conjugates for ADC	Cancer
Mc-Val-Cit-PAB-Gefitinib chloride is a agent-linker conjugates for ADC. Mc-Val-Cit-PAB-Gefitinib chloride consists of Gefitinib (HY-50895) (an EGFR tyrosine kinase inhibitor) and the ADC linker Mc-Val-Cit-PAB .

HY-126886

Mal-PEG1-NHS ester	ADC Linker PROTAC Linkers	Cancer
Mal-PEG1-NHS ester is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-NHS ester is PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-176478

PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC	ADC Linker	Cancer
PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC is an ADC linker that can be combined with the TLR7/8 agonist (HY-170770) for the synthesis of a linker-payload conjugate .

HY-148425

Mal-amide-PEG8-Val-Ala-PAB-PNP	ADC Linker	Cancer
Mal-amide-PEG8-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W101718

Fmoc-N-(2-Boc-aminoethyl)-Gly-OH	Isotope-Labeled Compounds ADC Linker	Cancer
Fmoc-N-(2-Boc-aminoethyl)-Gly-OH is a Fmoc-protected glycine derivative that can be used in antibody agent coupling (ADC) synthesis. ADC consists of antibodies that are linked to ADC cytotoxins via ADC junctions[1].

HY-164724

Bis-PEG30-NHS ester	ADC Linker	Cancer
Bis-PEG30-NHS ester is a non-claevable 30-unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126497

LC-PEG8-SPDP	ADC Linker	Cancer
LC-PEG8-SPDP is a cleavable ADC linker used for the antibody-drug conjugates (ADCs) .

HY-130222

Mal-PEG2-Val-Cit-PAB-OH	ADC Linker PROTAC Linkers	Cancer
Mal-PEG2-Val-Cit-PAB-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-Val-Cit-PAB-OH also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-101157

Propargyl-PEG5-acid	ADC Linker PROTAC Linkers	Cancer
Propargyl-PEG5-acid is a non-cleavable 5 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Propargyl-PEG5-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-117519A

Amino-Tri-(carboxyethoxymethyl)-methane hydrochloride	ADC Linker PROTAC Linkers	Cancer
Amino-Tri-(carboxyethoxymethyl)-methane hydrochloride is a cleavable PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(carboxyethoxymethyl)-methan hydrochloride is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-117519

Amino-Tri-(carboxyethoxymethyl)-methane	ADC Linker PROTAC Linkers	Cancer
Amino-Tri-(carboxyethoxymethyl)-methane is a cleavable PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) . Amino-Tri-(carboxyethoxymethyl)-methan is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-23641

NH-bis(C1-Boc)	ADC Linker	Cancer
NH-bis(C1-Boc)is a uncleavable linker used for antibody-drug conjugates (ADC).

HY-130161

m-PEG4-Br	ADC Linker PROTAC Linkers	Cancer
m-PEG4-Br is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-130442

Mal-PEG2-acid	ADC Linker PROTAC Linkers	Cancer
Mal-PEG2-acid is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-acid can be conjugated to Tubulysin (HY-128914) and its derivative cytotoxic molecule . Mal-PEG2-acid is also a PROTAC linker that can be used in the synthesis of PROTACs.

HY-140313A

Methyltetrazine-DBCO TEA	ADC Linker	Cancer
Methyltetrazine-DBCO TEA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyltetrazine-DBCO TEA is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. Methyltetrazine-DBCO TEA also contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-126851

Fluorescein-DBCO	Dyes
Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Fluorescein-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-123687

DBCO-Sulfo-NHS ester sodium	Dyes
DBCO-Sulfo-NHS ester sodium is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Fluorescent Dye
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78921AG

Fmoc-3VVD-OH (GMP)	Fluorescent Dye
Fmoc-3VVD-OH (GMP) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Fluorescent Dye
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Fluorescent Dye
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-42972G

DBCO-acid (GMP)

Fluorescent Dye

DBCO-acid GMP is a GMP grade DBCO-acid (HY-42972). DBCO-acid is a cleavable ADC linker used in the synthesis of ADC linker DBCO-NHS ester (HY-115524 and HY-115545), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690) . DBCO-acid is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100374G

Val-Cit-PAB-MMAE (GMP)	Fluorescent Dye
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Fluorescent Dye
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15575G

VcMMAE (GMP) MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)	Fluorescent Dye
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-12362G

Val-cit-PAB-OH (GMP)	Fluorescent Dye
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). Val-cit-PAB-OH is a degradable ADC linker.

HY-133540G

Maleimide-DOTA (GMP) Maleimido-mono-amide-DOTA (GMP)	Fluorescent Dye
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78738G

MC-Val-Cit-PAB (GMP)	Fluorescent Dye
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-45672G

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .

HY-W000423G

DBCO-amine (GMP)	Fluorescent Dye
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-19318G

Fmoc-Val-Cit-PAB (GMP)	Fluorescent Dye
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-78736G

Val-Cit-PAB-OSBT (GMP)	Fluorescent Dye
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .

HY-13631EG

Deruxtecan (GMP) MC-GGFG-DXD (GMP)	Fluorescent Dye
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy (GMP)	Fluorescent Dye
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Fluorescent Dye
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

Cat. No.	Product Name	Type

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Biochemical Assay Reagents
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135928

Biotin-C2-S-S-pyridine	Biochemical Assay Reagents
Biotin-C2-S-S-pyridine is a cleavable **ADC linker*. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs)* .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Biochemical Assay Reagents
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-163789

Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide	Biochemical Assay Reagents
Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-78921AG

Fmoc-3VVD-OH (GMP)	Biochemical Assay Reagents
Fmoc-3VVD-OH (GMP) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride (GMP)	Biochemical Assay Reagents
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78931G

Boc-Dap-NE (GMP)	Biochemical Assay Reagents
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-42972G

DBCO-acid (GMP)

Biochemical Assay Reagents

HY-100374G

Val-Cit-PAB-MMAE (GMP)	Biochemical Assay Reagents
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15575G

VcMMAE (GMP) MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)	Biochemical Assay Reagents
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-12362G

Val-cit-PAB-OH (GMP)	Biochemical Assay Reagents
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). Val-cit-PAB-OH is a degradable ADC linker.

HY-133540G

Maleimide-DOTA (GMP) Maleimido-mono-amide-DOTA (GMP)	Biochemical Assay Reagents
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78738G

MC-Val-Cit-PAB (GMP)	Biochemical Assay Reagents
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-45672G

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Biochemical Assay Reagents
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .

HY-W000423G

DBCO-amine (GMP)	Biochemical Assay Reagents
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-19318G

Fmoc-Val-Cit-PAB (GMP)	Biochemical Assay Reagents
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-78736G

Val-Cit-PAB-OSBT (GMP)	Biochemical Assay Reagents
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .

HY-13631EG

Deruxtecan (GMP) MC-GGFG-DXD (GMP)	Biochemical Assay Reagents
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy (GMP)	Biochemical Assay Reagents
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Biochemical Assay Reagents
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

Cat. No.	Product Name	Target	Research Area

HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH Mc-GGFG-PAB-OH	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA Mc-GGFG-PAB-OH TFA	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P4192

Fomc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit .

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate *(ADC)*.

HY-W008064

Fmoc-Cit-OH Fmoc-L-Citrulline	Amino Acid Derivatives	Cancer
Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .

HY-P5299

Fmoc-Gly-Gly-OSu	Biochemical Assay Reagents	Others
Fmoc-Gly-Gly-OSu (Compound 98-6) is a dipeptide that can be used to synthesize ADC linker .

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

HY-P2376

Arg-Phe-Asp-Ser	ADC Linker	Cancer
Arg-Phe-Asp-Ser is a cleavable ADC linker.

Cat. No.	Product Name	Target	Research Area

HY-164153

ADC Control Human IgG1-vcMMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99967

Cantuzumab	ADC Antibody	Cancer
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-111965

PF-06647263 anti-EFNA4-ADC	Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis	Cancer
PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .

HY-P9959

Inotuzumab ozogamicin CMC-544; PF-5208773; WAY-207294	Antibody-Drug Conjugates (ADCs) CD22 DNA/RNA Synthesis Apoptosis	Cancer
Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted *ADC* against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P9980

Belantamab GSK2857914	ADC Antibody TNF Receptor	Cancer
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .

HY-P99685

Laprituximab emtansine IMGN-289; J2898A-SMCC-DM1	EGFR Antibody-Drug Conjugates (ADCs)	Cancer
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an *ADC* composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99970

Lifastuzumab	ADC Antibody Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99493

Cantuzumab ravtansine IMGN242; huC242-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab ravtansine (IMGN242; huC242-DM4), an *ADC, is a humanized monoclonal antibody, huC242, covalently linked* via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99016B

Enfortumab vedotin-ejfv (solution)	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x

HY-P99662

Indusatumab vedotin MLN0264; TAK-264	Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis	Cancer
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .

HY-P99719

Lupartumab Amadotin BAY 1129980; Anti-C4.4a antibody-drug conjugates	Antibody-Drug Conjugates (ADCs)	Cancer
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an *ADC* comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting *ADC* comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-P99682

Ladiratuzumab hLIV22	ADC Antibody	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W034595

Eicosanedioic acid	Microorganisms Source classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-W034918

Docosanedioic acid	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

Cat. No.	Product Name	Chemical Structure

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-I1129

Fmoc-3VVD-OH-d8
Fmoc-3VVD-OH-d₈ is a deuterium labeled Fmoc-3VVD-OH (HY-78921). Fmoc-3VVD-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES3

Deruxtecan-d2
Deruxtecan-d₂ is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-79369S

Succinic anhydride-d4
Succinic anhydride-d₄ is the deuterium labeled Succinic anhydride. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide .

HY-13631ES2

Deruxtecan-d4-1
Deruxtecan-d₄-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-79369S1

Succinic anhydride-13C2
Succinic anhydride- ¹³C₂ is the ¹³C labeled Succinic anhydride . Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm . N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa .

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

ADC Linker

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products